ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1762

Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

Meeting: ACR Convergence 2023

Keywords: autoantigens, Gene Expression, Genomics and Proteomics, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However, there is limited information on the specificities, immunophenotype, and TCR diversity of antigen-specific T cells in RA using single-cell RNA sequencing (scRNA-seq). To address this knowledge gap, we conducted a pilot study to demonstrate the applicability of 10x single-cell sequencing for studying antigen-specific T cells.

Methods: Peripheral blood mononuclear cells (PBMC) were from patients with seropositive RA (n=3) and healthy control (HC) subjects (n=2). All individuals were HLA DRB1*0401 or 0404. Using an activation-induced marker (AIM) assay, PBMC were stimulated overnight with a pool of peptides derived from RA antigens (Table 1) or a peptide pool for viral antigens (CFEX). CD4+CD154+ and CD8+CD137+ cells were isolated to obtain paired scRNA-seq, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), and TCR repertoire data. Specifically, we isolated RA antigen-specific T cells, CEFX antigen-specific T cells, and general CD3 T cells from the same subjects (Figure 1). The sorted cells were stained with the TotalSeq Human Universal Cocktail (BioLegend), hashtagged, and the captured single cells sequenced using the droplet-based 10x Chromium platform. Cell projection and graph-based clustering were performed using the Seurat package.

Results: A total of 11,053 cells, 6464 from RA and 4589 from HC subjects, were subjected to high-quality scRNA-seq analysis. Utilizing a graph-based clustering approach, we identified seven distinct clusters of cells, representing both RA and HC, which were visualized through integrated UMAPs< ![if !supportAnnotations] >[VG1]< ![endif] > combining multimodal data. Overlaying hashtags to the UMAP suggests that RA and CEFX T cells mostly mapped to cluster 4. Differential gene expression analysis and antibody expression of established lineage markers revealed that cells in cluster 4 express high levels of activation markers including CD71, CD28, CD38, HLA-DR and KLRG1, transcription factors including NR4A1, HLA-A, HLA-B and IFNG, and translation initiation factorEIF5A and EIF1. We applied a similar graph-based clustering method to RA and CEFX antigen-reactive T cells, leading to the identification of four major clusters: a cytotoxic CD8+ T cells (cluster 0), exhausted CD8+ T cells (cluster 1), activated CD4+ T cells (cluster 2), and IFN I signature CD4+ T cells (cluster 3). We observed high-quality TCR sequences in over 90% of the captured cells from each subject and significant private clonal expansions, with CD8 RA antigen-specific T cells displaying a higher degree of clonotypic expansion compared to CD4 populations. We also identified clonal sharing between RA antigen-specific T cells and the non-selected CD3 T cells in each subject.

Conclusion: Our findings highlight the power of multimodal single cell analysis to identify clonally expanded T cells in RA, characterize their phenotypic features at rest and upon activation, which may provide valuable insights into the antigen-specific T-cell responses and TCR dynamics associated with RA pathology.

Supporting image 1

Table1 RA peptide pool.

Supporting image 2

Figure 1. Experimental design of 10X single cell RNA sequence using an AIM assay.


Disclosures: J. SONG: None; C. Rims: None; M. Dufort: None; P. Linsley: None; E. James: Bristol-Myers Squibb(BMS), 5, Janssen, 5, Novartis, 5, Provention Bio, 5; J. Buckner: Bristol-Myers Squibb(BMS), 2, gentibio, 1, 10, 11, hotspot therapeutics, 2, Janssen, 2.

To cite this abstract in AMA style:

SONG J, Rims C, Dufort M, Linsley P, James E, Buckner J. Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/single-cell-rna-sequencing-analysis-and-immune-profiling-of-antigen-specific-t-cells-in-patients-with-rheumatoid-arthritis-and-healthy-controls/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/single-cell-rna-sequencing-analysis-and-immune-profiling-of-antigen-specific-t-cells-in-patients-with-rheumatoid-arthritis-and-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology